Product image of Mertioscan (Mertiatide) supplied by GNH India

Mertioscan

Active Ingredient:
Mertiatide
Origin:
EU

Mertioscan (Mertiatide)

Mertiatide, the active ingredient in Mertioscan, is a peptide presented as an intravenous solution for infusion use. It is being investigated for potential therapeutic applications in specific disease contexts.
GNH India supplies Mertioscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Rotop Pharmaka Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mertioscan (mertiatide) currently has no publicly disclosed approved indications.

How It Works

  • The exact pharmacological mechanism of mertiatide has not been publicly disclosed. Available information suggests it is a synthetic peptide that may interact with cellular signaling pathways, but detailed target receptors or downstream effects remain proprietary.

Side Effects

Adverse‑reaction information for Mertioscan is limited in the public domain.

Common Side Effects

  • None reported in publicly available sources.

Serious or Rare Side Effects

  • None reported in publicly available sources.

Precautions & Warnings

When handling Mertioscan, consider general safety principles for intravenous biologics.

  • Patient monitoring: Observe for any unexpected clinical changes during infusion.
  • Compatibility: Verify compatibility with IV fluids before administration.
  • Infusion rate: Follow institutional protocols to avoid rapid administration.
  • Allergy assessment: Screen for known hypersensitivity to peptide products.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

No specific drug‑interaction data have been published for mertiatide.

Major Interactions (Avoid)

  • None identified in the literature.

Moderate Interactions (Monitor Closely)

  • Concomitant use of other investigational peptides: monitor for additive immunologic effects.
  • Immunosuppressants: observe for altered immune response.
  • Anticoagulants: watch for changes in coagulation parameters during infusion.

Frequently Asked Questions

Mertioscan contains the peptide mertiatide and is currently listed without publicly disclosed approved therapeutic indications. It is supplied for investigational or clinical trial use under the direction of qualified healthcare professionals.

The precise mechanism of mertiatide has not been made public. It is described as a synthetic peptide that may modulate cellular signaling pathways, but detailed target receptors and downstream effects are proprietary.

Dosing of Mertioscan is determined by the prescribing clinician based on the specific study protocol or therapeutic context. No standard dose is published for general use.

Safety data for mertiatide during pregnancy or lactation are not available. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant, and under strict medical supervision.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Direct comparative data are not publicly available. Mertioscan is a peptide formulation administered intravenously, and its clinical profile should be evaluated against other investigational or approved peptide agents on a case‑by‑case basis.

Mertioscan should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Mertioscan is supplied as an intravenous solution and is administered by slow infusion under controlled clinical conditions, following institutional protocols for IV peptide products.

Because specific safety data are limited, the most serious potential risks include unexpected allergic reactions, infusion‑related events, and unknown systemic effects. Continuous monitoring during administration is recommended.

Patients with known hypersensitivity to peptide products, or those for whom the investigational nature of the drug poses an unacceptable risk, should not receive Mertioscan. Final eligibility is determined by the treating physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mertiatide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT